About The Study: Among outpatient adults with mild to moderate COVID-19, treatment with fluvoxamine 100 mg twice daily for 13 days, compared with placebo, did not improve time to sustained recovery in this randomized clinical trial of 1,175 participants.
Authors: Susanna Naggie, M.D., M.H.S., of the Duke University School of Medicine in Durham, North Carolina, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link media.jamanetwork.com/
(doi:10.1001/jama.2023.23363)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
